Sarepta Therapeutics, Inc. Q2 2020 Earnings Conference Call
Forward Looking Statements

Wednesday, August 5, 2020 – 4:30 p.m. Eastern Time

In order to provide Sarepta's investors with an understanding of its current results and future prospects, forward-looking statements will be made during this conference call. Any statements made by Sarepta that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believe," "anticipate," "plan," "expect," "will," "may," "intend," "prepare," "look," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements relating to our future operations, financial performance and projections, business plans, market opportunities, priorities and research and development programs including: the expected or potential impact of the COVID-19 pandemic on our business, including the anticipation that any continuing impact from COVID-19 will remain modest; the potential of casimersen to treat 8% of the Duchenne community; the expectation that the PDUFA date for casimersen will be in Q1 2021 and the potential for a successful launch of casimersen; the potential to have 3 FDA-approved therapies, targeting nearly 30% of the Duchenne community and more than doubling the size of the treatable patient population since the approval of eteplirsen; PPMO's potential to profoundly improve the efficacy and convenience of our RNA technology; the PPMO platform's potential to treat diseases where our steric blocking RNA technology could provide therapeutic benefit; our belief that our unique approach to gene therapy research and development is first-in-class and replicable; engaging sites and obtaining IRB approvals for our next trial for SRP-9001 and gaining alignment with the FDA on the initiation of the study; the potential benefits of our collaborations with strategic partners; the expectation that the intake of START Forms will slowly increase as states ease restrictions; the expectation that over time eligible patients will ultimately receive access and reimbursement for VYONDYS 53 and EXONDYS 51 and start therapy in a timely manner; our belief that we can deal with and minimize the impacts on all of our future trials, in the face of surges in COVID-19 infections; the potential of the readout for MOMENTUM to extend to other PPMO Duchenne programs and other therapeutic areas; the potential of the PPMO candidates that we selected to treat 50% of Duchenne patients who carry skip amenable mutations in their dystrophin gene; our plan to bring the PPMO platform to the rarer exon populations, which has the potential to treat another 35% of the addressable population; and expected plans and milestones, including completing and releasing our safety tissue exposure, PK/PD, and comparative exon skipping for PPMO 5051 at 20 mgs/kg, completing Study 102 for SRP-9001 by the end of 2020 and having a read out in Q1 of 2021, commencing the next trial for SRP-9001 using commercial material in the second half of 2020, gaining alignment with the FDA on the initiation of our next trial for SRP-9001 using the GMP materials in Q3, commencing our pivotal trial for SRP-9003 in 2021, and providing an update on the LGMD discussions with the FDA and our GMP material for SRP-9003 in early 2021.

These forward-looking statements involve risks and uncertainties, many of which are beyond our control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: the COVID-19 pandemic is expected to reduce our revenue and may negatively impact our ongoing and planned clinical trials, manufacturing and other business operations; the commercial launch for VYONDYS 53 in the U.S. may not be successful for various reasons including the degree to which VYONDYS 53 is accepted by patients and prescribed by physicians, manufacturing limitations, and competitive, reimbursement and regulatory conditions that could negatively impact the launch; we may not be able to comply with all FDA post-approval commitments and requirements with respect to our products in a timely manner or at all; our dependence on certain manufacturers to produce our products and product candidates, including any inability on our part to accurately anticipate product demand and timely secure manufacturing capacity to meet product demand, may impair the availability of product to successfully support various programs; our data for casimersen, SRP-5051, SRP-9001, the LGMD programs and/or other programs may not be sufficient for obtaining regulatory approval; success in preclinical testing and early clinical trials, especially if based on a small patient sample, does not ensure that later clinical trials will be successful, and early results from a clinical trial do not necessarily predict final results; the expected benefits and opportunities related to our agreements with our strategic partners may not be realized or may take longer to realize than expected due to a variety of reasons, including any inability of the parties to perform their commitments and obligations under the agreements, challenges and uncertainties inherent in product research and development and manufacturing limitations; we may not be able to execute on our business plans, including meeting our expected or planned regulatory milestones and timelines, research and clinical development plans, and bringing our product candidates to market, for various reasons, many of which may be outside of our control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, and regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover our product candidates; and those risks identified under the heading "Risk Factors" in our most recent Annual Report on Form 10-K for the year ended December 31, 2019 and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review.

Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. You should not place undue reliance on forward-looking statements. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except to the extent required by applicable law or SEC rules.